Oxidant-induced cardiomyocyte injury: Identification of the cytoprotective effect of a dopamine 1 receptor agonist using a cell-based high-throughput assay

International Journal of Molecular Medicine

Volumn 20, Issue 5, 2007, Pages 749-761

  Gerö, Domokos ^a   Módis, Katalin ^a   Nagy, Nóra ^a   Szoleczky, Petra ^a   Tóth, Zoltán Dóri ^a   Dormán, György ^b   Szabó, Csaba ^a,c  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^b AMRI   (Hungary)

^c University of Medicine and Dentistry of New Jersey   (United States)

Author keywords

Apoptosis; Cell necrosis; High content screening; High throughput screening; Myocardial infarction; Oxidative stress; Poly(ADP ribose) polymerase

Indexed keywords

BROMIDE; DOPAMINE RECEPTOR STIMULATING AGENT; HYDROGEN PEROXIDE; N (5,6 DIHYDRO 6 OXO 2 PHENANTHRIDINYL) 2 DIMETHYLAMINOACETAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OXIDIZING AGENT; PHENANTHRENE DERIVATIVE;

ANIMAL; ARTICLE; BIOASSAY; CELL DEATH; CELL PROTECTION; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; ENZYME ACTIVATION; HEART MUSCLE CELL; METABOLISM; METHODOLOGY; MOLECULAR LIBRARY; OXIDATIVE STRESS; PATHOLOGY; RAT;

ANIMALS; BIOLOGICAL ASSAY; BROMIDES; CELL DEATH; CYTOPROTECTION; DOPAMINE AGONISTS; DRUG EVALUATION, PRECLINICAL; ENZYME ACTIVATION; HYDROGEN PEROXIDE; MYOCYTES, CARDIAC; OXIDANTS; OXIDATIVE STRESS; PHENANTHRENES; POLY(ADP-RIBOSE) POLYMERASES; RATS; SMALL MOLECULE LIBRARIES;

EID: 38449115536     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Braunwald E and Kloner RA: Myocardial reperfusion: a double-edged sword? J Clin Invest 76: 1713-1719, 1985.
2. Moens AL, Claeys MJ, Timmermans JP and Vrints CJ: Myocardial ischemia/reperfusion-injury, a clinical view on a complex pathophysiological process. Int J Cardiol 100: 179-190, 2005.
3. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K and Mitchinson MJ: Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 347: 781-786, 1996.
4. Chouairi S, Carrie D and Puel J: Myocardial protection with calcium-channel blockers during ischaemia and reperfusion by PTCA. Eur Heart J 16 (suppl H): 3-8, 1995.
5. Narins CR, Miller DP, Califf RM and Topol EJ: The relationship between periprocedural myocardial infarction and subsequent target vessel revascularization following percutaneous coronary revascularization: insights from the EPIC trial. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in preventing ischemic complications. J Am Coll Cardiol 33: 647-653, 1999.
6. Ferrari R, Pepi P, Ferrari F, Nesta F, Benigno M and Visioli O: Metabolic derangement in ischemic heart disease and its therapeutic control. Am J Cardiol 82: 2K-13K, 1998.
7. Zweier JL: Measurement of superoxide-derived free radicals in the reperfused heart. Evidence for a free radical mechanism of reperfusion injury. J Biol Chem 263: 1353-1357, 1988.
8. Maxwell SR and Lip GY: Reperfusion injury: a review of the pathophysiology, clinical manifestations and therapeutic options. Int J Cardiol 58: 95-117, 1997.
9. Bianchi C, Wakiyama H, Faro R, et al: A novel peroxynitrite decomposer catalyst (FP-15) reduces myocardial infarct size in an in vivo peroxynitrite decomposer and acute ischemia-reperfusion in pigs. Ann Thorac Surg 74: 1201-1207, 2002.
10. Ferrari R, Guardigli G, Mele D, Percoco GF, Ceconi C and Curello S: Oxidative stress during myocardial ischaemia and heart failure. Curr Pharm Des 10: 1699-1711, 2004. (Pubitemid 38559780)
11. Zingarelli B, Cuzzocrea S, Zsengeller Z, Salzman AL and Szabó C: Protection against myocardial ischemia and reperfusion injury by 3-aminobenzamide, an inhibitor of poly (ADP-ribose) synthetase. Cardiovasc Res 36: 205-215, 1997.
12. Zingarelli B, Salzman AL and Szabó C: Genetic disruption of poly (ADP-ribose) synthetase inhibits the expression of P-selectin and intercellular adhesion molecule-1 in myocardial ischemia/reperfusion injury. Circ Res 83: 85-94, 1998. (Pubitemid 28322102)
13. Faro R, Toyoda Y, McCully JD, et al: Myocardial protection by PJ34, a novel potent poly (ADP-ribose) synthetase inhibitor. Ann Thorac Surg 73: 575-581, 2002.
14. Jagtap P and Szabó C: Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov 4: 421-440, 2005.
15. Toth-Zsamboki E, Horvath E, Vargova K, et al: Activation of poly(ADP-ribose) polymerase by myocardial ischemia and coronary reperfusion in human circulating leukocytes. Mol Med 12: 221-228, 2006.
16. Jagtap P, Soriano FG, Virag L, et al: Novel phenanthridinone inhibitors of poly (adenosine 5′-diphosphate-ribose) synthetase: potent cytoprotective and antishock agents. Crit Care Med 30: 1071-1082, 2002.
17. Gilad E, Zingarelli B, Salzman AL and Szabó C: Protection by inhibition of poly (ADP-ribose) synthetase against oxidant injury in cardiac myoblasts in vitro. J Mol Cell Cardiol 29: 2585-2597, 1997. (Pubitemid 27404449)
18. Virag L, Scott GS, Antal-Szalmas P, O'Connor M, Ohshima H and Szabó C: Requirement of intracellular calcium mobilization for peroxynitrite-induced poly(ADP-ribose) synthetase activation and cytotoxicity. Mol Pharmacol 56: 824-833, 1999.
19. Alano CC, Kauppinen TM, Valls AV and Swanson RA: Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrations. Proc Natl Acad Sci USA 103: 9685-9690, 2006.
20. Szabó C, Pacher P and Swanson RA: Novel modulators of poly(ADP-ribose) polymerase. Trends Pharmacol Sci 27: 626-630, 2006.
21. Wang H, Liao H, Ochani M, et al: Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med 10: 1216-1221, 2004.
22. Kulkarni DS and Saraf AP: Antagonism of isoproterenol-induced cardiac necrosis in mice by adenosine, dipyridamole and prenylamine. Indian Heart J 30: 220-223, 1978.
23. Rabkin SW: Effect of chlorpromazine on myocardial damage in the calcium paradox. J Cardiovasc Pharmacol 9: 486-492, 1987.
24. McLean KM, Duffy JY, Pandalai PK, et al: Glucocorticoids alter the balance between pro- and anti-inflammatory mediators in the myocardium in a porcine model of brain death. J Heart Lung Transplant 26: 78-84, 2007.
25. Skyschally A, Haude M, Dorge H, et al: Glucocorticoid treatment prevents progressive myocardial dysfunction resulting from experimental coronary microembolization. Circulation 109: 2337-2342, 2004.
26. Tsuchida A, Liu GS, Wilborn WH and Downey JM: Pretreatment with the adenosine A1 selective agonist, 2-chloro-N6-cyclopentyladenosine (CCPA), causes a sustained limitation of infarct size in rabbits. Cardiovasc Res 27: 652-656, 1993. (Pubitemid 23144591)
27. Neely CF, DiPierro FV, Kong M, Greelish JP and Gardner TJ: A1 adenosine receptor antagonists block ischemia-reperfusion injury of the heart. Circulation 94: II376-II380, 1996.
28. Yang Z, Cerniway RJ, Byford AM, Berr SS, French BA and Matherne GP: Cardiac overexpression of A1-adenosine receptor protects intact mice against myocardial infarction. Am J Physiol Heart Circ Physiol 282: H949-H955, 2002.
29. Virag L, Salzman AL and Szabó C: Poly(ADP-ribose) synthetase activation mediates mitochondrial injury during oxidant-induced cell death. J Immunol 161: 3753-3759, 1998.
30. Zweier JL and Talukder MA: The role of oxidants and free radicals in reperfusion injury. Cardiovasc Res 70: 181-190, 2006.
31. Hartman DS and Lanau F: Diversity of dopamine receptors: new molecular and pharmacological developments. Pol J Pharmacol 49: 191-199, 1997.
32. Zhang A, Neumeyer JL and Baldessarini RJ: Recent progress in development of dopamine receptor subtype-selective agents: potential therapeutics for neurological and psychiatric disorders. Chem Rev 107: 274-302, 2007. (Pubitemid 46237370)
33. Sams-Dodd F: Target-based drug discovery: is something wrong? Drug Discov Today 10: 139-147, 2005.
34. Degterev A, Huang Z, Boyce M, et al: Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol 1: 112-119, 2005.
35. Williams M: Target validation. Curr Opin Pharmacol 3: 571-577, 2003.
36. Dormán G, Krajcsi P, Puskás L, et al: Recent advances in chemical genomics. Front Med Chem 3: 503-550, 2006.
37. Dormán G and Darvas F: Utilizing small molecules in chemical genomics: toward HT approaches. In: Chemical Genomics. Darvas F, Guttman A and Dormán G (eds). Marcel Dekker, New York, Basel, pp137-197, 2004.
38. Butcher EC: Can cell systems biology rescue drug discovery? Nat Rev Drug Discov 4: 461-467, 2005.